Dyax Issued Fifth U.S. Patent in Its Phage Display Patent Portfolio
"This recently issued patent adds to Dyax's already dominant patent position in the phage display field. Our discovery technology platform continues to provide Dyax and our collaborators the ability to take almost any target of interest and identify novel compounds that selectively bind to it," said Ivana Magovcevic-Liebisch, General Counsel and Executive Vice President, Corporate Communications of Dyax Corp. "For example, our human antibody phage display libraries can be screened against a selected target to identify high-affinity antibodies that can be developed as new therapeutics."
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous